The promise and challenges of immune agonist antibody development in cancer (Q56891562)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

title

The promise and challenges of immune agonist antibody development in cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

Patrick A Mayes

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

Kenneth W Hance

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

Axel Hoos

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

language of work or name

English

0 references

publication date

15 June 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

Nature Reviews Drug Discovery

31 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

509-527

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

The blockade of immune checkpoints in cancer immunotherapy

31 March 2020

cites work

1 reference

TNF/TNFR family members in costimulation of T cell responses

31 March 2020

1 reference

The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.

31 March 2020

1 reference

Association between genetic variations in tumor necrosis factor receptor genes and survival of patients with T-cell lymphoma.

31 March 2020

1 reference

Integrated molecular analysis of adult T cell leukemia/lymphoma.

31 March 2020

1 reference

Association of OX40L polymorphisms with sporadic breast cancer in northeast Chinese Han population

31 March 2020

1 reference

ICOS deficiency in patients with common variable immunodeficiency.

31 March 2020

1 reference

The basic principles of chimeric antigen receptor design

31 March 2020

1 reference

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

31 March 2020

1 reference

Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations

31 March 2020

1 reference

An enigmatic tail of CD28 signaling

31 March 2020

1 reference

Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients

31 March 2020

1 reference

Protective effector memory CD4 T cells depend on ICOS for survival

31 March 2020

1 reference

ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28

31 March 2020

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

CTLA4Ig: bridging the basic immunology with clinical application

31 March 2020

1 reference

Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

31 March 2020

1 reference

T-cell co-stimulation through B7RP-1 and ICOS

31 March 2020

1 reference

ICOS is essential for effective T-helper-cell responses

31 March 2020

1 reference

The TNF and TNF receptor superfamilies: integrating mammalian biology

31 March 2020

1 reference

The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games

31 March 2020

1 reference

TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future

31 March 2020

1 reference

Death receptor-ligand systems in cancer, cell death, and inflammation

31 March 2020

1 reference

Regulation of tumour necrosis factor signalling: live or let die

31 March 2020

1 reference

OX40 is differentially expressed on activated rat and mouse T cells and is the sole receptor for the OX40 ligand

31 March 2020

1 reference

Stimulation of CD25( )CD4( ) regulatory T cells through GITR breaks immunological self-tolerance

31 March 2020

1 reference

Structural mechanisms of costimulation

31 March 2020

1 reference

Structure and dimerization of a soluble form of B7-1

31 March 2020

1 reference

Crystal structure of the receptor-binding domain of human B7-2: Insights into organization and signaling

31 March 2020

1 reference

Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses

31 March 2020

1 reference

Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

31 March 2020

1 reference

The immunological synapse: a molecular machine controlling T cell activation

31 March 2020

1 reference

B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse

31 March 2020

1 reference

Immunology. The immunological synapse--a multitasking system

31 March 2020

1 reference

Crystal structure of a soluble CD28-Fab complex

31 March 2020

1 reference

The kinetic-segregation model: TCR triggering and beyond

31 March 2020

1 reference

A distinct role for ICOS-mediated co-stimulatory signaling in CD4 and CD8 T cell subsets.

31 March 2020

1 reference

CD28 Costimulation: From Mechanism to Therapy

31 March 2020

1 reference

ICOS ligation recruits the p50alpha PI3K regulatory subunit to the immunological synapse

31 March 2020

1 reference

The crystal structure of the costimulatory OX40-OX40L complex

31 March 2020

1 reference

Structural basis of inducible costimulator ligand costimulatory function: determination of the cell surface oligomeric state and functional mapping of the receptor binding site of the protein.

31 March 2020

1 reference

The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily

31 March 2020

1 reference

The molecular architecture of the TNF superfamily

31 March 2020

1 reference

TNF alpha and the TNF receptor superfamily: structure-function relationship(s).

31 March 2020

1 reference

Tumor necrosis factor receptor and Fas signaling mechanisms.

31 March 2020

1 reference

The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity

31 March 2020

1 reference

A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling

31 March 2020

1 reference

Identification and characterization of a ligand-independent oligomerization domain in the extracellular region of the CD95 death receptor

31 March 2020

1 reference

Human glucocorticoid-induced TNF receptor ligand regulates its signaling activity through multiple oligomerization states

31 March 2020

1 reference

Downregulation of Fas ligand by shedding

31 March 2020

1 reference

Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex

31 March 2020

1 reference

Structural basis for ligand-mediated mouse GITR activation

31 March 2020

1 reference

Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.

31 March 2020

1 reference

Structural basis of signal transduction in the TNF receptor superfamily

31 March 2020

1 reference

The TNF-receptor-associated factor family: scaffold molecules for cytokine receptors, kinases and their regulators

31 March 2020

1 reference

The binding sites for competitive antagonistic, allosteric antagonistic, and agonistic antibodies to the I domain of integrin LFA-1.

31 March 2020

1 reference

A series of Fas receptor agonist antibodies that demonstrate an inverse correlation between affinity and potency

31 March 2020

1 reference

Principles of antibody-mediated TNF receptor activation

31 March 2020

1 reference

Anti-Fas IgG1 antibodies recognizing the same epitope of Fas/APO-1 mediate different biological effects in vitro

31 March 2020

1 reference

Targeting death and decoy receptors of the tumour-necrosis factor superfamily

31 March 2020

1 reference

TRAIL and its receptors as targets for cancer therapy

31 March 2020

1 reference

Epitopes and functional responses defined by a panel of anti-Fas (CD95) monoclonal antibodies

31 March 2020

1 reference

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

31 March 2020

1 reference

Pharmacological modulation of GITRL/GITR system: therapeutic perspectives.

31 March 2020

1 reference

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

31 March 2020

1 reference

Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antibody agonists

31 March 2020

1 reference

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

31 March 2020

1 reference

Bispecific antibodies and their applications

31 March 2020

1 reference

Despite slow progress, bispecifics generate buzz.

31 March 2020

1 reference

Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling

31 March 2020

1 reference

Multivalent 4-1BB binding aptamers costimulate CD8 T cells and inhibit tumor growth in mice.

31 March 2020

1 reference

Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer

31 March 2020

1 reference

Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain

31 March 2020

1 reference

Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand

31 March 2020

1 reference

FcγR requirements leading to successful immunotherapy

31 March 2020

1 reference

Antibodies, Fc receptors and cancer

31 March 2020

1 reference

Roles of Fc receptors in autoimmunity

31 March 2020

1 reference

Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412.

31 March 2020

1 reference

Cell contact-dependent priming and Fc interaction with CD32 immune cells contribute to the TGN1412-triggered cytokine response

31 March 2020

1 reference

Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody.

31 March 2020

1 reference

Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization

31 March 2020

1 reference

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

31 March 2020

1 reference

Fcγ receptors enable anticancer action of proapoptotic and immune-modulatory antibodies

31 March 2020

1 reference

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

31 March 2020

1 reference

Influence of immunoglobulin isotype on therapeutic antibody function

31 March 2020

1 reference

Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerization

31 March 2020

1 reference

Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.

31 March 2020

1 reference

Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer

31 March 2020

1 reference

Apoptotic and antitumor activity of death receptor antibodies require inhibitory Fcγ receptor engagement

31 March 2020

1 reference

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses

31 March 2020

1 reference

Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

31 March 2020

1 reference

Antibody therapy of cancer

31 March 2020

1 reference

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

31 March 2020

1 reference

Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

31 March 2020

1 reference

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

31 March 2020

1 reference

"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics

31 March 2020

1 reference

Toward experimental assessment of receptor occupancy: TGN1412 revisited

31 March 2020

1 reference

Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists

31 March 2020

1 reference

Costimulation Through the CD137/4-1BB Pathway Protects Human Melanoma Tumor-infiltrating Lymphocytes From Activation-induced Cell Death and Enhances Antitumor Effector Function

31 March 2020

1 reference

Colloidal drug formulations can explain "bell-shaped" concentration-response curves

31 March 2020

1 reference

Molecular and cellular insights into T cell exhaustion

31 March 2020

1 reference

Activating and inhibitory FcgammaRs in autoimmune disorders.

31 March 2020

1 reference

Monoclonal antibodies: versatile platforms for cancer immunotherapy

31 March 2020

1 reference

IgG subclasses and allotypes: from structure to effector functions

31 March 2020

1 reference

31 March 2020

1 reference

Fcgamma receptors as regulators of immune responses

31 March 2020

1 reference

Fc-receptors as regulators of immunity.

31 March 2020

1 reference

Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect

31 March 2020

1 reference

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

31 March 2020

1 reference

OX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacy

31 March 2020

1 reference

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

31 March 2020

1 reference

OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection

31 March 2020

1 reference

Triggering of OX40 (CD134) on CD4( )CD25 T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR.

31 March 2020

1 reference

Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells

31 March 2020

1 reference

Gene structure and chromosomal assignment of mouse GITR, a member of the tumor necrosis factor/nerve growth factor receptor family

31 March 2020

1 reference

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer

31 March 2020

1 reference

Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer

31 March 2020

1 reference

Anti-CD30 Antibodies for Hodgkin lymphoma.

31 March 2020

1 reference

Development of a human monoclonal antibody for potential therapy of CD27-expressing lymphoma and leukemia

31 March 2020

1 reference

Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice

31 March 2020

1 reference

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

31 March 2020

1 reference

Regulatory T cells in cancer immunotherapy

31 March 2020

1 reference

CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth

31 March 2020

1 reference

CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help

31 March 2020

1 reference

CD40 ligation for immunotherapy of solid tumours

31 March 2020

1 reference

CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans

31 March 2020

1 reference

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors

31 March 2020

1 reference

Agonistic CD40 antibodies and cancer therapy

31 March 2020

1 reference

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

31 March 2020

1 reference

The role of the CD40 pathway in the pathogenesis and treatment of cancer.

31 March 2020

1 reference

CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily

31 March 2020

1 reference

CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.

31 March 2020

1 reference

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

31 March 2020

1 reference

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

31 March 2020

1 reference

Rationale for anti-OX40 cancer immunotherapy

31 March 2020

1 reference

Science gone translational: the OX40 agonist story

31 March 2020

1 reference

OX40 is a potent immune-stimulating target in late-stage cancer patients

31 March 2020

1 reference

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

31 March 2020

1 reference

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

31 March 2020

1 reference

ICOS Promotes the Function of CD4 Effector T Cells during Anti-OX40-Mediated Tumor Rejection

31 March 2020

1 reference

Rationale for anti-GITR cancer immunotherapy

31 March 2020

1 reference

Pivotal roles of CD4 effector T cells in mediating agonistic anti-GITR mAb-induced-immune activation and tumor immunity in CT26 tumors

31 March 2020

1 reference

Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens

31 March 2020

1 reference

Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy

31 March 2020

1 reference

Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells.

31 March 2020

1 reference

Chimeric antigen receptor T cells for sustained remissions in leukemia

31 March 2020

1 reference

Engineered T cells: the promise and challenges of cancer immunotherapy.

31 March 2020

1 reference

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

31 March 2020

1 reference

Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors

31 March 2020

1 reference

Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production

31 March 2020

1 reference

Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.

31 March 2020

1 reference

Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.

31 March 2020

1 reference

Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors

31 March 2020

1 reference

Targeting CD137 enhances the efficacy of cetuximab.

31 March 2020

1 reference

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

31 March 2020

1 reference

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

31 March 2020

1 reference

Agonist antibodies to TNFR molecules that costimulate T and NK cells

31 March 2020

1 reference

Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice

31 March 2020

1 reference

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

31 March 2020

1 reference

CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice

31 March 2020

1 reference

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

31 March 2020

1 reference

Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 effector memory T-cells

31 March 2020

1 reference

Preculture of PBMCs at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN1412.

31 March 2020

1 reference

The storm has cleared: lessons from the CD28 superagonist TGN1412 trial

31 March 2020

1 reference

Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.

31 March 2020

1 reference

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.

31 March 2020

1 reference

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

31 March 2020

1 reference

Anti-CTLA-4 therapy results in higher CD4 ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues

31 March 2020

1 reference

Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy

31 March 2020

1 reference

Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade

31 March 2020

1 reference

PD-1 signaling in primary T cells

31 March 2020

1 reference

Potent activity of soluble B7RP-1-Fc in therapy of murine tumors in syngeneic hosts

31 March 2020

1 reference

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity

31 March 2020

1 reference

ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4 T cells

31 March 2020

1 reference

Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy.

31 March 2020

1 reference

A soluble hexameric form of CD40 ligand activates human dendritic cells and augments memory T cell response

31 March 2020

1 reference

Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell death

31 March 2020

1 reference

A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model

31 March 2020

1 reference

LIGHT protein suppresses tumor growth by augmentation of immune response.

31 March 2020

1 reference

Priming of naive T cells inside tumors leads to eradication of established tumors

31 March 2020

1 reference

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

31 March 2020

1 reference

GITR ligand fusion protein agonist enhances the tumor antigen-specific CD8 T-cell response and leads to long-lasting memory.

31 March 2020

1 reference

A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist

31 March 2020

1 reference

MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential

31 March 2020

1 reference

Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand

31 March 2020

1 reference

Both extracellular immunoglobin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28

31 March 2020

1 reference

CTLA-4 Overexpression Inhibits T Cell Responses through a CD28-B7-Dependent Mechanism

31 March 2020

1 reference

B7-1 and B7-2: similar costimulatory ligands with different biochemical, oligomeric and signaling properties

31 March 2020

1 reference

CD80 and CD86 IgC domains are important for quaternary structure, receptor binding and co-signaling function

31 March 2020

1 reference

Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptor

31 March 2020

1 reference

Induction, binding specificity and function of human ICOS

31 March 2020

1 reference

B7-H2 Is a Costimulatory Ligand for CD28 in Human

31 March 2020

1 reference

LICOS, a primordial costimulatory ligand?

31 March 2020

1 reference

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

31 March 2020

1 reference

Impact of epidermal growth factor receptor (EGFR) cell surface expression levels on effector mechanisms of EGFR antibodies

31 March 2020

1 reference

Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg

31 March 2020

1 reference

7 January 2021

inferred from DOI database lookup

T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody

1 reference

7 January 2021

inferred from DOI database lookup

Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens

1 reference

12 December 2020

CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location

1 reference

12 December 2020

The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding

1 reference

12 December 2020

Characterization of a cell surface-expressed disulfide-linked dimer involved in murine T cell activation

1 reference

12 December 2020

Synergy between the T3/antigen receptor complex and Tp44 in the activation of human T cells

1 reference

12 December 2020

Antibodies to distinct epitopes on the CD40 molecule co-operate in stimulation and can be used for the detection of soluble CD40

1 reference

12 December 2020

Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors

1 reference

12 December 2020

The TNF ligand superfamily and its relevance for human diseases

1 reference

12 December 2020

Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.

1 reference

12 December 2020

All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction

1 reference

12 December 2020

Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2018.75

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29904196 AND SRC:MED&resulttype=core&format=json

31 March 2020

1 reference